M&A Deal Summary

Curewell Capital Acquires Wilmington PharmaTech

On October 21, 2025, growth capital firm Curewell Capital acquired life science company Wilmington PharmaTech

Acquisition Highlights

This is Curewell Capital’s 1st transaction in the Life Science sector.
This is Curewell Capital’s 1st transaction in the United States.
This is Curewell Capital’s 1st transaction in Delaware.

M&A Deal Summary
Date	2025-10-21
Target	Wilmington PharmaTech
Sector	Life Science
Buyer(s)	Curewell Capital
Deal Type	Buyout (LBO, MBO, MBI)
Advisor(s)	Potter Anderson & Corroon (Legal)

Target

Wilmington PharmaTech

Newark, Delaware, United States

Wilmington PharmaTech is a specialty contract research, development, and manufacturing organization (CRDMO) focused on custom small molecule API development and manufacturing. It operates two adjacent state-of-the-art facilities with extensive cGMP manufacturing capabilities, including dedicated high potency API (HPAPI) suites, as well as registered starting material (RSM) support and R&D facility in Suzhou, China. Wilmington PharmaTech is based in Newark, Delaware.

Search 214,107 Deals Now

SEARCH BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Try Free

Buyer(S) 1

Buyer